Boston Scientific Vitalyst

Healthcare product naming

Since 1979, Boston Scientific has been a global leader in medical technology, providing a broad range of high-performance solutions that address unmet patient needs while reducing healthcare costs. It developed an innovative pVAD (percutaneous ventricular assist device) to support heart function during high-risk interventions to treat coronary disease. In this minimally invasive system, a miniature heart pump accesses the heart through a vessel in the leg. Once positioned, it keeps blood flowing to vital organs. The system’s design reduces set-up time, simplifies workflow, more securely positions the pump, and eliminates the need for a purge line, all of which reduce patient complications and improve health outcomes. 

As a long-time client, Boston Scientific turned to Catchword to develop a name for this life-saving technology. Vitalyst instantly conveys the critical need the system meets and the vitality it preserves while recalling the precision and transformation of analyst and catalyst. The company will begin clinical trials for Vitalyst later in 2024.

Client
Boston Scientific
Boston Scientific
Industry
Health & Biotech
Service
Product Naming
VitalystFeaturedImage_1800x695.jpg
Naming the First Line

We explored a number of naming styles and messaging areas that would reach both busy physicians (who want a practical and professional name that communicates the product’s function and benefits immediately) and consumers/patients (who need a smart yet friendly name that strongly reassures them that taking this test will be easy and in their best interest). DELFI FirstLook does it all. An intuitive, approachable name that’s easy to say, spell, and remember for people with even minimal English. The line provides the earliest look into possible cancer and is the first screening product of its kind. And it’s both a shorthand for the early detection the test provides and a call to action: “First look” (then treat).

Outcome

DELFI FirstLook Lung launched in October 2023 as the first liquid biopsy test in the US with a high-sensitivity for early lung cancer detection. The product established DELFI as a leading innovator in the space, and the name created an easy-to-use yet robust naming convention for future DELFI products. In April 2024, DELFI announced its collaboration with City of Hope, one of the largest cancer research and treatment organizations in the US, to use FirstLook Lung to help improve screening rates in underserved communities in Los Angeles County. The test will be offered free to eligible trial participants.

"Our whole-genome machine learning platform is designed to be widely scalable for flexible global deployment. FirstLook Lung is the first of a deep pipeline of tests that we are developing for an array of cancers as well as to monitor the progress of cancer treatments."

Jenn Buechel, DELFI President and Chief Operating Officer

Related Case Studies

Carefree Sleepwear

Antech Diagnostic Tools

OnShift